Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by AstraZeneca.
Recruitment status was  Active, not recruiting
Information provided by:
AstraZeneca Identifier:
First received: September 27, 2007
Last updated: January 21, 2009
Last verified: January 2009

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Condition Intervention
Coronary Heart Disease
Carotid Stenosis
Peripheral Vascular Diseases
Diabetes Mellitus
Drug: Any cholesterol-lowering drug

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Non-Interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Estimated Enrollment: 1600
Study Start Date: September 2007

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Exclusion Criteria:

  • Patients who do not receive cholesterol-lowering therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00536796

Research Site
Rohrbach, Upper Austria, Austria
Sponsors and Collaborators
Study Chair: Josef Patsch, MD Chair of the Austrian Atheroslerosis Society
Study Chair: Bernhard Foger, MD Co-Chair of the Austrian Atheroslerosis Society
  More Information

No publications provided Identifier: NCT00536796     History of Changes
Other Study ID Numbers: NIS-CAT-CRE-2007/2
Study First Received: September 27, 2007
Last Updated: January 21, 2009
Health Authority: Not required for this study:

Keywords provided by AstraZeneca:
Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes

Additional relevant MeSH terms:
Carotid Stenosis
Coronary Artery Disease
Coronary Disease
Diabetes Mellitus
Heart Diseases
Myocardial Ischemia
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Brain Diseases
Cardiovascular Diseases
Carotid Artery Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Endocrine System Diseases
Glucose Metabolism Disorders
Lipid Metabolism Disorders
Metabolic Diseases
Nervous System Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on October 20, 2014